Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial-Reference-Cited by-同舟云学术

Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

Published:2020-09-06 Issue:10 Volume:72 Page:1694-1706
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Yazici Yusuf¹,McAlindon Timothy E.²,Gibofsky Allan³^ORCID,Lane Nancy E.⁴,Clauw Daniel⁵,Jones Morgan⁶,Bergfeld John⁶,Swearingen Christopher J.⁷,DiFrancesco Anita⁷,Simsek Ismail⁷,Tambiah Jeyanesh⁷,Hochberg Marc C.⁸

Affiliation:

1. Samumed LLC San Diego California

2. Tufts Medical Center Boston Massachusetts

3. Weill Cornell Medical College New York New York

4. UC Davis Medical School Burlingame California

5. University of Michigan Ann Arbor

6. Cleveland Clinic Cleveland Ohio

7. Samumed, LLC San Diego California

8. University of Maryland School of Medicine Baltimore Maryland

Publisher

Wiley

Subject